ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pemetrexed

Also written as “pemetrexed”, “ALIMTA” and “Pemetrexed/Cisplatin”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Neoplasms · Ovarian Neoplasms · Colorectal Neoplasms, led by 9 companies.

Drug pagePemetrexed: every studyMany companies study it; this page follows only the 108 they lead. All 434 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 22, 2006108 company-led studies, 4 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only940 open or runningphase 4since Sep 22, 2006Apr 29, 2002none ahead
Hoffmann-La Rocheits history only72 open or runningphase 3since Aug 18, 2009Aug 18, 2009Jun 30, 2027phase 3 · NCT05112965
Betta Pharmaceuticalsits history only10 open or runningphase 4since Mar 31, 2014Mar 31, 2014none ahead
Hikma Pharmaceuticals10 open or runningphase 4since Feb 26, 2018Feb 26, 2018none ahead
Johnson & Johnsonits history only11 open or runningphase 3since Aug 31, 2020Aug 31, 2020none ahead
NovoCureits history only10 open or runningphase 2since Mar 19, 2015Mar 19, 2015none ahead
Polaris Groupits history only10 open or runningphase 3since Mar 5, 2016Mar 5, 2016none ahead
Shanghai Miracogenits history only11 open or runningphase 3since Feb 22, 2023Feb 22, 2023none ahead
Takedaits history only10 open or runningphase 2since Jun 22, 2006Jun 22, 2006none ahead

Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Parexel, Daiichi Sankyo, Arcus Biosciences, Ono Pharmaceutical and Prologue Research International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hikma Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 26, 2018First study: phase 4 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03460678 · 9 enrolled · Jordan, Lebanon

TargetBeta

“Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor; Dihydrofolate reductase inhibitor”ChEMBL 37, by rule

Studies

The one study Hikma Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03460678Carcinoma, Non-Small-Cell Lung · Jordan, Lebanon4TerminatedNov 14, 20189

How it is read

Names in the registry

  • “Pemetrexed”, 74 entries
  • “pemetrexed”, 51 entries
  • “ALIMTA”, 7 entries
  • “Pemetrexed/Cisplatin”, 2 entries
  • “Pemetrexed/Carboplatin”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.